CSBio CSBio

X
[{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Gets Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"Tesla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Taps Tesla for 'RNA Microfactories,' Elon Musk Says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Nets EU Funding to Ramp up Vaccine Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"BioNTech","sponsor":"Temasek","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$139.0 million","newsHeadline":"Temasek Leads a $250M Raise for BioNTech as First Covid-19 mRNA Vaccine Data Looms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"CureVac","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Announces Proposed Initial Public Offering of Common Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"German Federal Ministry of Education and Research","pharmaFlowCategory":"D","amount":"$297.8 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Germany Approves Third Trial of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"IDT Biologika GmbH"},{"orgOrder":0,"company":"Evotec","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evotec Starts Clinical Development of Chikungunya Antibody Together with NIAID and Leading Academic Research Organisation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Evotec"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"Curetis","sponsor":"BioVersys AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Curetis"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on First BioNTainer for African-based mRNA Manufacturing Facility","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Announces Proposed Public Offering of Common Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"BioNTech","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI\u2019s 100 Days Mission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The partnership aims to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox (formerly monkeypox, caused by a member of the Orthopoxvirus viral family), an infectious disease that can lead to severe, life-threatening complications.

            Lead Product(s): BNT166

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT166

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $90.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership September 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CV0501 (mRNA-based prophylactic vaccine) is a monovalent mRNA vaccine candidate using modified nucleosides, encoding the S protein of Omicron BA.1 and maintaining the same pre-fusion stabilizing mutations in S protein.

            Lead Product(s): mRNA-based Prophylactic Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: CV0501

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Goldman Sachs & Co.

            Deal Size: $250.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company intends to use the net proceeds from the offering primarily for the development of CV0501(mRNA-based prophylactic vaccine), and for general corporate purposes.

            Lead Product(s): mRNA-based Prophylactic Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: CV0501

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC

            Deal Size: $200.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CV0501 is the first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19. It encodes the prefusion stabilized full-length spike protein of the SARS-CoV-2 Omicron variant BA.1 and is formulated with lipid nanoparticles (LNPs).

            Lead Product(s): CV0501

            Therapeutic Area: Infections and Infectious Diseases Product Name: CV0501

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CV0501 was designed with specifically optimized non-coding regions aiming to deliver improved mRNA translation for increased and extended protein expression compared to the first-generation mRNA backbone.

            Lead Product(s): CV0501

            Therapeutic Area: Infections and Infectious Diseases Product Name: CV0501

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The trial designed to assess the safety, tolerability, and immunogenicity of the vaccine component, BNT165b1, an ribonucleic acid (RNA)-lipid nanoparticle (LNP) encoding for part of the Plasmodium falciparum circumsporozoite protein (PfCSP).

            Lead Product(s): BNT165

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT165

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BioNTech’s proprietary BNT165 program is part of the Company’s Malaria project and has a key objective to develop a well-tolerated and highly effective mRNA vaccine with durable protective immunity to prevent blood-stage Malaria infection.

            Lead Product(s): BNT165

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT165

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The mRNA vaccine BNT163, encodes three HSV-2 glycoproteins with the aim of helping to prevent HSV cellular entry and spread, as well as counteract the immunosuppressive properties of HSVs.

            Lead Product(s): BNT163

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT163

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BNT162b2 mRNA vaccine program, a combination vaccine candidate for influenza and COVID-19 and Pfizer-BioNTech Vaccine, also known as COMIRNATY (COVID-19 Vaccine, mRNA), including the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5 (BNT162b2).

            Lead Product(s): BNT162b2,qIRV

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b2

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BV100 is a much-needed injectable formulation of rifabutin to treat serious infections caused by Carbapenem Resistant Acinetobacter baumannii in patients with ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia and bloodstream infections.

            Lead Product(s): Rifabutin

            Therapeutic Area: Infections and Infectious Diseases Product Name: BV100

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: BioVersys AG

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY